Ion Beam Applications SA (IBA) is a company that represents a set of values and a corporate philosophy focused on innovation, sustainability, and patient-centricity. As a leading global provider of proton therapy and other advanced cancer treatments, IBA aims to deliver personalized and efficient solutions to enhance the quality of life for cancer patients. With a strong emphasis on research and development, IBA continuously strives to improve treatment outcomes and expand its technological capabilities. Through its commitment to ethical business practices, collaboration, and social responsibility, IBA aims to make a positive impact in the healthcare industry while driving long-term value for its stakeholders.

Ion Beam Applications SA is primarily present in various countries and regions around the world. Some of the key markets where the company has a significant presence include Europe, North America, Asia-Pacific, and Latin America. With its global reach, Ion Beam Applications SA has established a strong foothold in the medical, industrial, and research sectors in these regions. As a leader in advanced ion beam solutions, Ion Beam Applications SA continues to expand its presence and provide its cutting-edge technologies and services to customers in numerous countries and regions globally.

Ion Beam Applications SA (IBA) has achieved several significant milestones throughout its history. One notable accomplishment is the company's introduction of the first proton therapy system, which revolutionized cancer treatment by delivering precise and targeted radiation therapy. Another milestone for IBA was the development of innovative solutions for proton therapy treatment planning, resulting in improved treatment accuracy and patient outcomes. Additionally, IBA has successfully expanded its global footprint, establishing a strong presence in key markets worldwide, including Europe, the United States, and Asia. With a commitment to continuous innovation and technological advancements, IBA continues to solidify its position as a leader in the field of particle therapy.

Ion Beam Applications SA (IBA) is a renowned company that specializes in proton therapy and radiopharmacy solutions for cancer treatment. Founded in 1986, IBA has grown to become a global leader in its field. With a strong focus on innovation and research, the company has developed cutting-edge technologies and products that have revolutionized cancer care. IBA's proton therapy systems offer precise and non-invasive treatment options, minimizing side effects and improving patient outcomes. Additionally, its radiopharmacy solutions provide hospitals and medical centers with the necessary tools for personalized and targeted cancer treatments. With a commitment to advancing cancer care, IBA continues to play a crucial role in the fight against cancer worldwide.

The main competitors of Ion Beam Applications SA in the market include Accuray Incorporated, Varian Medical Systems Inc., and Elekta AB. These companies are leading players in the medical equipment industry, offering advanced radiation therapy and oncology solutions similar to those provided by Ion Beam Applications SA. However, Ion Beam Applications SA differentiates itself through its cutting-edge proton therapy technology, which sets it apart from its competitors. With its innovative offerings and strong market presence, Ion Beam Applications SA continues to compete effectively in the medical equipment industry.

Ion Beam Applications SA, also known as IBA, is primarily active in the healthcare industry. With their advanced proton therapy and radiopharmacy solutions, IBA plays a crucial role in the treatment of cancer and other diseases. Their innovative technologies enable precise targeting of tumors while minimizing damage to surrounding healthy tissues. Through close collaborations with leading medical institutions and research centers worldwide, IBA continues to drive advancements in proton therapy, making it an invaluable player in improving patients' lives.

The business model of Ion Beam Applications SA (IBA) is focused on providing advanced solutions for cancer treatment and diagnosis. As a leading provider in the field of proton therapy, IBA designs, develops, and markets cutting-edge proton therapy systems, including cyclotrons and treatment facilities. Making use of high-energy proton beams, IBA's innovative technology enables precise and targeted irradiation to tumors, minimizing damage to surrounding healthy tissues. By offering comprehensive solutions for particle accelerators, proton therapy centers, and radiopharmacy, IBA aims to improve the quality of life for patients suffering from cancer worldwide.

The Ion Beam Applications P/E ratio is 59.58.

The Ion Beam Applications P/S ratio is 0.81.

The Quality Investing for Ion Beam Applications is 5/10.

The expected Ion Beam Applications revenue is 481.51 M EUR.

The expected Ion Beam Applications profit is 6.55 M EUR.

Ion Beam Applications SA (IBA) is a leading provider of proton therapy and radiation therapy systems, diagnostic radiopharmaceuticals, customized radiopharmaceuticals, as well as dosimetry systems and software solutions. The company has been active in the industry for over 30 years and is headquartered in Louvain-la-Neuve, Belgium. Proton therapy is an innovative technology for cancer treatment. It is based on the use of proton beams that selectively destroy the tumor while protecting healthy tissue. IBA offers proton therapy systems suitable for both clinics and research purposes. The systems are modular and can be customized to meet the individual needs of customers. In addition to proton therapy, IBA also offers radiation therapy systems that enable precise and accurate tumor irradiation. The systems are used in radio-oncology, neurosurgery, and gynecology, among others. Furthermore, IBA is a leading manufacturer of diagnostic radiopharmaceuticals used for the diagnosis and monitoring of cancer. The radiopharmaceuticals are produced using IBA products, which ensure high quality and reproducibility. IBA also offers customized radiopharmaceuticals tailored to the specific needs of individual clinics. IBA is also active in dosimetry, providing solutions for measuring the dose of radiation. IBA's dosimetry systems are precise, reliable, and used worldwide. Additionally, IBA offers software solutions that enable effective planning and monitoring of radiation therapy. IBA's ion technology is another business area. The company is a leading provider of ion beam systems used in the semiconductor industry, materials research, and medicine. The ion beam systems enable precise material processing and are also suitable for the production of microchips and electronic components. Overall, IBA's business model is diverse and encompasses a variety of products and services in different industries. The company focuses on innovation and technological excellence to provide its customers with the best possible solutions. With a strong emphasis on quality and customer satisfaction, IBA is an important partner for customers in the medical, research, and industrial sectors.

Ion Beam Applications pays a dividend of 0.19 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Ion Beam Applications or the company does not pay out a dividend.

The ISIN of Ion Beam Applications is BE0003766806.

The WKN of Ion Beam Applications is 914998.

The ticker of Ion Beam Applications is IBAB.BR.

Over the past 12 months, Ion Beam Applications paid a dividend of 0.21 EUR . This corresponds to a dividend yield of about 1.57 %. For the coming 12 months, Ion Beam Applications is expected to pay a dividend of 0.21 EUR.

The current dividend yield of Ion Beam Applications is 1.57 %.

Ion Beam Applications pays a quarterly dividend. This is distributed in the months of July, July, July, July.

Ion Beam Applications paid dividends every year for the past 7 years.

For the upcoming 12 months, dividends amounting to 0.21 EUR are expected. This corresponds to a dividend yield of 1.57 %.

Ion Beam Applications is assigned to the 'Health' sector.

To receive the latest dividend of Ion Beam Applications from 7/1/2024 amounting to 0.18 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

The last dividend was paid out on 7/1/2024.

In the year 2023, Ion Beam Applications distributed 0.19 EUR as dividends.

The dividends of Ion Beam Applications are distributed in EUR.